Cartesian Therapeutics (RNAC) Competitors $11.37 +0.48 (+4.41%) Closing price 04:00 PM EasternExtended Trading$11.52 +0.16 (+1.36%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. AMPH, DYN, ABCL, PAHC, WVE, ELVN, VERV, NTLA, COLL, and AKBAShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health WAVE Life Sciences Enliven Therapeutics Verve Therapeutics Intellia Therapeutics Collegium Pharmaceutical Akebia Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do institutionals and insiders hold more shares of RNAC or AMPH? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, RNAC or AMPH? Cartesian Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Does the media prefer RNAC or AMPH? In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Amphastar Pharmaceuticals and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.87 beat Amphastar Pharmaceuticals' score of 0.44 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cartesian Therapeutics Very Positive Amphastar Pharmaceuticals Neutral Do analysts prefer RNAC or AMPH? Cartesian Therapeutics presently has a consensus price target of $41.25, suggesting a potential upside of 262.80%. Amphastar Pharmaceuticals has a consensus price target of $32.33, suggesting a potential upside of 37.12%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has higher valuation & earnings, RNAC or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M7.58-$77.42M-$52.83-0.22Amphastar Pharmaceuticals$731.97M1.52$159.52M$2.768.54 Is RNAC or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 19.38% compared to Cartesian Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Cartesian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -7.01% Amphastar Pharmaceuticals 19.38%22.20%10.40% SummaryAmphastar Pharmaceuticals beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$282.64M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.2221.3126.1719.90Price / Sales7.58278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book-42.117.518.055.38Net Income-$77.42M-$55.05M$3.15B$248.50M7 Day Performance5.67%2.45%1.85%2.97%1 Month Performance13.93%7.33%4.81%6.02%1 Year Performance-27.90%5.38%34.86%20.39% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.9779 of 5 stars$11.37+4.4%$41.25+262.8%-55.1%$282.64M$38.91M-0.2264Positive NewsAMPHAmphastar Pharmaceuticals4.2872 of 5 stars$22.96-0.5%$32.33+40.8%-39.4%$1.09B$731.97M8.322,028DYNDyne Therapeutics3.4938 of 5 stars$9.52-0.5%$41.13+332.0%-75.5%$1.09BN/A-2.65100ABCLAbCellera Biologics2.2401 of 5 stars$3.43-5.0%$8.33+143.0%+25.5%$1.08B$28.83M-6.12500High Trading VolumePAHCPhibro Animal Health3.5669 of 5 stars$25.54-0.5%$21.80-14.6%+56.2%$1.04B$1.02B32.741,940WVEWAVE Life Sciences4.5404 of 5 stars$6.50-2.5%$20.50+215.4%+24.4%$1.04B$108.30M-7.74240Positive NewsELVNEnliven Therapeutics2.4691 of 5 stars$20.06-3.0%$39.60+97.4%-13.4%$1.01BN/A-10.4550Analyst ForecastVERVVerve Therapeutics3.5023 of 5 stars$11.23-0.6%$14.57+29.8%+126.5%$1.01B$32.33M-5.32110NTLAIntellia Therapeutics4.6699 of 5 stars$9.38-1.9%$33.37+255.7%-56.0%$990.25M$57.88M-1.79600COLLCollegium Pharmaceutical4.0327 of 5 stars$29.57-1.2%$43.75+48.0%-7.1%$961.71M$664.28M24.24210News CoverageAKBAAkebia Therapeutics4.3431 of 5 stars$3.64-0.3%$6.75+85.4%+259.0%$958.62M$160.18M-17.33430News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies AMPH Competitors DYN Competitors ABCL Competitors PAHC Competitors WVE Competitors ELVN Competitors VERV Competitors NTLA Competitors COLL Competitors AKBA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
